Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology
Proceedings of the National Academy of Sciences · 2023
DOI: 10.1073/pnas.2214350120 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Nadia Bannoud und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Glicobiología y Biología Vascular, Instituto de Histología y Embriología de Mendoza, Consejo Nacional de Investigaciones Científicas y…. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Melanoma. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Research UK, Department of Health, MINCyT | ANPCyT | Fondo para la Investigación Científica y Tecnológica.
Abstract (Originalsprache)
Blockade of vascular endothelial growth factor (VEGF) signaling with bevacizumab, a humanized anti-VEGF monoclonal antibody (mAb), or with receptor tyrosine kinase inhibitors, has improved progression-free survival and, in some indications, overall survival across several types of cancers by interrupting tumor angiogenesis. However, the clinical benefit conferred by these therapies is variable, and tumors from treated patients eventually reinitiate growth. Previously we demonstrated, in mouse tumor models, that galectin-1 (Gal1), an endogenous glycan-binding protein, preserves angiogenesis in anti-VEGF–resistant tumors by co-opting the VEGF receptor (VEGFR)2 signaling pathway in the absence of VEGF. However, the relevance of these findings in clinical settings is uncertain. Here, we explored, in a cohort of melanoma patients from AVAST-M, a multicenter, open-label, randomized controlled phase 3 trial of adjuvant bevacizumab versus standard surveillance, the role of circulating plasma Gal1 as part of a compensatory mechanism that orchestrates endothelial cell programs in bevacizumab-treated melanoma patients. We found that increasing Gal1 levels over time in patients in the bevacizumab arm, but not in the observation arm, significantly increased their risks of recurrence and death. Remarkably, plasma Gal1 was functionally active as it was able to reprogram endothelial cell biology, promoting migration, tubulogenesis, and VEGFR2 phosphorylation. These effects were prevented by blockade of Gal1 using a newly developed fully human anti-Gal1 neutralizing mAb. Thus, using samples from a large-scale clinical trial from stage II and III melanoma patients, we validated the clinical relevance of Gal1 as a potential mechanism of resistance to bevacizumab treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Glicobiología y Biología Vascular, Instituto de Histología y Embriología de Mendoza, Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad Nacional de Cuyo, Mendoza 5500, Argentina.
- Laboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires 1428, Argentina.
- Laboratorio de Glicómica Funcional y Molecular, Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires 1428, Argentina.
- Instituto de Tecnología, Universidad Argentina de la Empresa, Buenos Aires 1073, Argentina.
- Warwick Clinical Trials Unit, University of Warwick, Coventry CV4 7AL, UK.
- Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
ORCID-Profile: Alejandro J Cagnoni, Karina V Mariño, Diego O Croci
Förderung
- Cancer Research UK
- Department of Health
- MINCyT | ANPCyT | Fondo para la Investigación Científica y Tecnológica
- Richard Lounsbery Foundation
- NIHR | NIHR Cambridge Biomedical Research Centre
Zitieren
APA
Bannoud, N., Stupirski, J. C., Cagnoni, A. J., Hockl, P. F., Pérez Sáez, J. M., García, P. A., Mahmoud, Y. D., Gambarte Tudela, J., Scheidegger, M. A., Marshall, A., Corrie, P. G., Middleton, M. R., Mariño, K. V., Girotti, M. R., Croci, D. O., & Rabinovich, G. A. (2023). Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2214350120
Vancouver
Bannoud N, Stupirski JC, Cagnoni AJ, Hockl PF, Pérez Sáez JM, García PA, et al. Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2214350120
BibTeX
@article{Bannoud2023,
author = {Bannoud, Nadia and Stupirski, Juan C and Cagnoni, Alejandro J and Hockl, Pablo F and Pérez Sáez, Juan M and García, P Alfredo and Mahmoud, Yamil D and Gambarte Tudela, Julián and Scheidegger, Marco A and Marshall, Andrea and Corrie, Pippa G and Middleton, Mark R and Mariño, Karina V and Girotti, M Romina and Croci, Diego O and Rabinovich, Gabriel A},
title = {Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
doi = {10.1073/pnas.2214350120}
}
EUVIMED